Five Billionaire-Owned Biotech Stocks You Could Acquire for 100%
That 40% premium is in addition to the nearly 70% gain the stock has experienced this month, driven by the takeover speculation . And for InterMune shareholders of the past five months, they are now sitting on a 250% gain.
Read More: Warren Buffett's Top 10 Dividend Stocks
Orbimed, one of the biggest and best billionaire healthcare hedge funds in the world, owned more than 5% of InterMune. Today's opening price increases the value of Orbimed's stake by $100 million, compared to Friday's close.
M&A in the biotech sector is on pace to break a record in 2014. We've seen more than $87 billion in deals done as large pharmaceutical companies are buying smaller biotech's to expand into new markets and find new pockets of growth.
In our research at BillionairesPortfolio.com, we have found that in almost every single takeover deal in the biotech sector, there has been the presence of a top billion-dollar hedge fund that has owned a controlling stake in the target company. The great thing about takeovers is that they can occur in any market condition, bear or bull.
With that, the five stocks listed below all have the potential to be acquired for a 100% premium or more, and each are heavily owned by a top hedge fund or billionaire investor:
Read More: 10 Stocks George Soros Is Buying
1) Array BioPharma
3) Amicus Therapeutics
4) Seattle Genetics
5) Repros Therapeutics